Altogether 2419 patients with wet AMD, included in VIEW 1 and 2 studies, were randomized (after initial 3 monthly doses) to receive intravitreal aflibercept 2.0 mg every 8 weeks (2q8), aflibercept 2.0 mg every 4 weeks, aflibercept 0.5 mg every 4 weeks or ranibizumab 0.5 mg every 4 weeks (0.5q4) «Yuzawa M, Fujita K, Wittrup-Jensen KU ym. Improvem...»1. The 25-iten National Eye Institute Visual Function Questionnaire (NEI VFQ-25) was administered at baseline and at weeks 12, 24, 36 and 52. The NEI VFC-21 subscales were compared between aflibercept 2q8 and ranibizumab 0.5q4 groups. There were no differences in NEI VFQ-25 scores at the baseline. Also mean increase from baseline to 52 weeks was similar for aflibercept 2q8 and ranibizumab 0.5q4 groups (7.3 and 7.8 points, respectively), with clinically meaningfull improvement recorded in 6 of 12 subscales (general vision, near activities, distance activities, mental health, role difficulties and dependency). Improvement in NEI VFQ-25 scores was seen in only those patients who gained more than 5 EDTRS letters.